From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Last Updated: Monday, April 14, 2025

Researchers evaluated atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor. They found that dose intensification led to greater CDK4 inhibition and deeper antitumor responses. Combinatorial agents also further increased atirmociclib’s antitumor efficacy.

Cancer Cell
Advertisement
News & Literature Highlights
Advertisement
Advertisement